PSMA PET/CT could also play a part in the decision-making of intermediate-risk PCa suitability for active surveillance by identifying patients with high volume Gleason pattern 4 disease and differentiating ISUP GG 3 from ISUP GG 2 disease. This evidence concerns the gene FOLH1 and posterior cortical atrophy.